Scientific Knowledge
Xenon Pharmaceuticals Inc.
Company
Publicly traded biopharmaceutical company (NASDAQ: XENE). Developer of azetukalner (XEN1101), a Kv7 potassium channel opener in Phase 3 development for focal epilepsy and major depressive disorder/bipolar depression. No tinnitus program.
Explore connections· click any item to explore